12:00 AM
Jun 22, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Onsolis regulatory update

BioDelivery said FDA had missed the June 12 action date for an NDA for Onsolis (formerly BEMA fentanyl) to treat breakthrough cancer pain in opioid-tolerant patients, though the agency told the company that it would...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >